EMEA-002516-PIP01-18

Key facts

Active substance
Lonafarnib
Therapeutic area
Other
Decision number
P/0258/2019
PIP number
EMEA-002516-PIP01-18
Pharmaceutical form(s)
Capsule (hard)
Condition(s) / indication(s)
  • Treatment of Hutchinson-Gilford Progeria Syndrome
  • Treatment of progeroid laminopathies
Route(s) of administration
Oral use
Contact for public enquiries
Eiger BioPharmaceuticals Europe Limited

Tel. +(+1) 877 899 2051
E-mail: info@eigerbio.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating